Upgrade to SI Premium - Free Trial

J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data

March 9, 2023 1:01 PM
J.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot List

Next Articles